UAE Launches Next-Gen GPS-Less Navigation and Secure Flight Control to Strengthen Aviation Security
18.2.2025 14:19:00 CET | Business Wire | Press release
VentureOne and ADASI Partner to Integrate Advanced Autonomous Flight Technologies Powered by TII – Perceptra and Saluki Unveiled at IDEX 2025
As dual-use technologies increasingly drive economies of scale worldwide, ADASI, a leader in UAV system manufacturing, has announced their adoption of two advanced autonomous flight technologies by Abu Dhabi’s VentureOne: Perceptra, a new cutting-edge GPS-less navigation technology, and Saluki, a high-security flight control technology for autonomous systems.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218620933/en/

UAE Launches Next-Gen GPS-Less Navigation and Secure Flight Control to Strengthen Aviation Security (Photo: AETOSWire)
These technologies, both developed by the Technology Innovation Institute, are designed to deliver secure, resilient operations in the most challenging environments. They have been optimized for UAV manufacturers, offering enhanced resilience, precision, and security for autonomous aerial operations. The agreement between VentureOne, ADASI, and TII was formalized at IDEX 2025, the Middle East’s largest defense exhibition, at which Saluki and Perceptra were unveiled.
Global Positioning System (GPS) technology has long been a fundamental pillar of navigation, supporting applications from everyday smartphone use to critical defense and military operations. However, this widespread reliance on GPS has exposed vulnerabilities that can be exploited through techniques like jamming and spoofing. Jamming occurs when signals on the same frequency overwhelm GPS receivers, preventing accurate location tracking, while spoofing involves transmitting counterfeit signals to deceive receivers into calculating incorrect positions or times. These vulnerabilities pose significant risks across sectors that depend on precise navigation, including autonomous drones, commercial aviation, and military aircraft.
In defense and security, compromised GPS signals can impact mission success and personnel safety, while in aviation, navigation errors may cause flight path deviations and operational disruptions – reports of which have the aviation industry and international regulators such as IATA and European regulator EASA seeking urgent solutions for GPS interference, according to one Reuters report in 2024.
For autonomous systems like drones and self-driving vehicles, the inability to maintain accurate positioning can create safety hazards, particularly in dynamic or high-risk environments, from aviation to defense. As the use of GPS-dependent systems continues to grow, the need for resilient, alternative navigation solutions has become increasingly critical. Perceptra and Saluki overcome many of today’s numerous challenges with advanced vision-based navigation, delivering reliable, resilient performance.
Dr. Najwa Aaraj, CEO of TII, said, “Perceptra, with its GPS-less capabilities, and Saluki, with its sophisticated Zero Trust architecture, represent a significant leap in autonomous navigation with the potential to transform multiple sectors. From supporting safe travel in commercial flights, search-and-rescue missions with precise navigation, to enabling efficient urban drone logistics for deliveries in densely populated cities, these technologies have broad real-world applications. Their adaptability also makes them invaluable in defense, ensuring secure and resilient operations in even the most challenging environments. This collaboration reflects our commitment to developing advanced, dual-use technologies that serve both civilian and defense needs while positioning the UAE as a leader in next-generation autonomous systems.”
Perceptra is a vision-based system that ensures reliable navigation without GPS, allowing aerial platforms to operate in GNSS-denied environments. It features visual relocking, low navigation errors, and easy integration across platforms for intelligence, surveillance, reconnaissance, and electronic warfare.
Saluki is a secure, high-performance flight controller and mission computer with Zero Trust architecture. With PX4 compatibility, Gen AI capabilities, and 300 TOPS compute power, it supports multi-vehicle management for mission-critical defense applications.
“At ADASI, we integrate only the most advanced, field-proven technologies to ensure our UAVs operate with unmatched precision, resilience, and security, even in the most contested environments,” said Juma Al Kaabi, the CEO of ADASI. “Perceptra and Saluki provide exactly what next-generation UAVs require: secure, GPS-independent navigation and AI-powered mission control.”
“VentureOne is dedicated to ensuring that cutting-edge research becomes reality to make a positive impact and transform industries,” said Reda Nidhakou, the Acting CEO of VentureOne. “Saluki and Perceptra are just two of many new innovations to come that will help ensure more resilient and safer drone operations in different sectors, starting with defense. We are working on a more comprehensive air autonomy and security portfolio that will play a central role in future drone operations.”
Last week, TII announced its collaboration with the General Civil Aviation Authority (GCAA) to support regulatory efforts by developing advanced methodologies for air corridor design. These methodologies aim to optimize flight routes and reduce the risk of aerial incidents in complex urban airspaces, ensuring safe and efficient navigation for both piloted and autonomous drone taxis. These efforts, alongside Perceptra and Saluki, reinforce Abu Dhabi’s vision to lead in next-generation navigation and AI-powered autonomy.
Both VentureOne and TII are part of the Advanced Technology Research Council (ATRC), which oversees Abu Dhabi’s research and development ecosystem to advance transformative technologies with global impact. ADASI is part of the EDGE Group, the advanced technology and defense conglomerate.
Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20250218620933/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom